Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

285 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Hanauer SB, et al. Among authors: lukas m. Gastroenterology. 2006 Feb;130(2):323-33; quiz 591. doi: 10.1053/j.gastro.2005.11.030. Gastroenterology. 2006. PMID: 16472588 Clinical Trial.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J; European Crohn's and Colitis Organisation (ECCO). Van Assche G, et al. Among authors: lukas m. J Crohns Colitis. 2010 Feb;4(1):63-101. doi: 10.1016/j.crohns.2009.09.009. Epub 2009 Dec 21. J Crohns Colitis. 2010. PMID: 21122490 No abstract available.
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M. Bortlik M, et al. Among authors: lukas m, lukas m. Scand J Gastroenterol. 2016;51(2):196-202. doi: 10.3109/00365521.2015.1079924. Epub 2015 Sep 2. Scand J Gastroenterol. 2016. PMID: 26329773
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Bortlik M, et al. Among authors: lukas m, lukas m. Scand J Gastroenterol. 2013 Aug;48(8):951-8. doi: 10.3109/00365521.2013.812141. Epub 2013 Jul 8. Scand J Gastroenterol. 2013. PMID: 23834232
Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children.
Bortlik M, Duricova D, Machkova N, Kozeluhova J, Kohout P, Hrdlicka L, Durilova M, Mitrova K, Hradsky O, Bronsky J, Malickova K, Lukas M. Bortlik M, et al. Among authors: lukas m. Inflamm Bowel Dis. 2014 Mar;20(3):495-501. doi: 10.1097/01.MIB.0000440984.86659.4f. Inflamm Bowel Dis. 2014. PMID: 24407486
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Regueiro M, et al. Among authors: lukas m. Gastroenterology. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3. Gastroenterology. 2016. PMID: 26946343 Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. Among authors: lukas m. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Clinical Trial.
Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients.
Pedersen N, Duricova D, Lenicek M, Elkjaer M, Bortlik M, Andersen PS, Vitek L, Davidsen B, Wewer V, Lukas M, Munkholm P. Pedersen N, et al. Among authors: lukas m. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1196-203. doi: 10.1097/MEG.0b013e32833dde2e. Eur J Gastroenterol Hepatol. 2010. PMID: 20739896
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Sandborn WJ, et al. Among authors: lukas m. Gastroenterology. 2009 Dec;137(6):1934-43.e1-3. doi: 10.1053/j.gastro.2009.08.069. Epub 2009 Sep 18. Gastroenterology. 2009. PMID: 19766640 Clinical Trial.
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Sands BE, et al. Among authors: lukas m. Inflamm Bowel Dis. 2017 Jan;23(1):97-106. doi: 10.1097/MIB.0000000000000979. Inflamm Bowel Dis. 2017. PMID: 27930408 Clinical Trial.
285 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback